Armata Pharmaceuticals’ investigational phage therapy, AP-SA02, demonstrated earlier resolution in patients with Staphylococcus aureus bacteremia (SAB) in a Phase IIa trial, reinforcing the growing ...
Despite challenges like high treatment costs and antibiotic resistance, strategic R&D investments and precision medicine innovations are shaping its futureDublin, Dec. 16, 2025 (GLOBE NEWSWIRE) -- The ...
* Cubicin clinically proven to target both Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA) with equal efficacy[1] * These serious infections can cause death in up to ...
Armata Pharmaceuticals ARMP shares have skyrocketed 72.3% in the past month. The massive surge in the stock price was observed after the company announced positive top-line results from its early to ...
cleaner with mop and uniform cleaning hall floor of public business building Implementation of an environmental cleaning bundle in Australia was associated with a decrease in infectious caused by S ...
The report to Ayrshire and Arran Health Board says the infections have risen in both hospitals and community settings ...
SAB Biotherapeutics’ DiversitAb novel drug development platform creates targeted fully human multi-epitope binding immunoglobulins (polyclonal antibodies) without the need for human donors. Its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback